Cabergoline can increase penile erections and libido

Neurology

Volumn 58, Issue 5, 2002, Pages 831-

  Wittstock, Matthias ^a   Benecke, Reiner ^a   Dressler, Dirk ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMLODIPINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; CABERGOLINE; ROPINIROLE;

AGED; ARTICLE; CASE REPORT; DIABETES MELLITUS; DRUG EFFECT; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; LIBIDO; MALE; PARKINSON DISEASE; PENIS ERECTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS;

EID: 0037066079     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.5.831     Document Type: Article

References (7)

1. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
2. Efficacy and safety of fixed-dose and dose-optimization regimes of sublingual apomorphine versus placebo in men with erectile dysfunction
3. Dose-induced penile erections in response to ropinirole therapy for Parkinson's disease
4. Cabergoline treatment rapidly improves gonadal function in hyperprolactinaemic males: A comparison with bromocriptine
5. Opposite influence of medial preoptic D1 and D2 receptors on genital reflexes: Implications for copulation
6. Paraventricular nucleus lesion prevents yawning and penile erection induced by apomorphine and oxytocin but not by ACTH in rats
7. Decreased number of oxytocin-immunoreactive neurons in the paraventricular nucleus of the hypothalamus in Parkinson's disease